Press releases

^{Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.}

YearType

2026

23 Feb 2026, 17:00

Hansa Biopharma presenting at TD Cowen’s 46th Annual Health Care Conference

18 Feb 2026, 19:53 | Regulatory

Hansa Biopharma’s Biologics License Application (BLA) for imlifidase accepted by the FDA

11 Feb 2026, 07:00 | Regulatory

Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

· Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024.
· Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation.
· Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M).

26 Jan 2026, 12:15

Hansa Biopharma to host Year-end report 2025 conference call

22 Jan 2026, 13:30

Hansa Biopharma has won the 2025 SwedenBIO Award